Please login to the form below

Not currently logged in
Email:
Password:

pancreatic cancer

This page shows the latest pancreatic cancer news and features for those working in and with pharma, biotech and healthcare.

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Advanced pancreatic cancer is notoriously hard to treat, and Eli Lilly’s pegilodecakin has joined the list of drugs unable to improve survival compared to standard chemotherapy. ... Pancreatic cancer is currently the seventh leading cause of cancer

Latest news

More from news
Approximately 24 fully matching, plus 109 partially matching documents found.

Latest Intelligence

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    the only PARP inhibitor with positive phase 3 results in four different cancer types (ovarian, breast, pancreatic and prostate). ... First we had ovarian cancer, then breast cancer, and our next steps will be for metastatic pancreatic cancer and men with

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.

  • Finding the patient voice Finding the patient voice

    Mr Whitley took part in a pancreatic cancer drug trial in 2011.

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.  . ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer,

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    1. MM-398 a nanoliposomal irinotecan injection of for metastatic pancreatic cancer in phase III. ... 805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics